31 – 40 of 131
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Clinical effects of Lewy body pathology in cognitively impaired individuals
(
- Contribution to journal › Article
-
Mark
Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia
(
- Contribution to journal › Article
-
Mark
Plasma phosphorylated tau 217 in preclinical Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Plasma p-tau181 and p-tau217 in discriminating PART, AD and other key neuropathologies in older adults
(
- Contribution to journal › Article
-
Mark
Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients : A multi-cohort study
(
- Contribution to journal › Article
-
Mark
Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients
(
- Contribution to journal › Article
-
Mark
The genetic regulation of protein expression in cerebrospinal fluid
(
- Contribution to journal › Article
-
Mark
Plasma IAPP-Autoantibody Levels in Alzheimer’s Disease Patients Are Affected by APOE4 Status
(
- Contribution to journal › Article
-
Mark
Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals
(
- Contribution to journal › Article